Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$236.9MCash on Hand
CF+ Cash Runway
Follow PGNY by emailGet an email when PGNY pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PGNY, unsubscribe in one click. Privacy
🧪 Trial & FDA Catalysts
Jun 2015 · N/A · Results Expected · Eeva™ Pregnancy Investigational Clinical Study: A Postmarket Follow-Up Study Registry primary completion date, not a results date
Dec 2014 · N/A · Results Expected · Correlating Time-Lapse Parameters Detected by the Eeva™ System With Comprehensive Chromoso Registry primary completion date, not a results date
Feb 2013 · N/A · Results Expected · Eeva™ Continued Access Study: Assessing the Usability of Eeva in a Clinical Setting Registry primary completion date, not a results date
Aug 2012 · N/A · Results Expected · Eeva 12-well Dish Study Registry primary completion date, not a results date
Apr 2012 · N/A · Results Expected · Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured Registry primary completion date, not a results date
💰 Cash Runway & Dilution Risk
PGNY holds $236.9M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PGNY and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.